April 1, 2019 09:42 AM EDT

Merck's Keytruda wins first checkpoint inhibitor lung cancer approval in China; Puma sells rights to Nerlynx in Europe, parts of Africa for $60M upfront

Natalie Grover

Reporter

→ Merck’s entrenched flagship Keytruda immunotherapy has just scored a key lung cancer approval in China. The drug, already sanctioned for use in advanced melanoma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck's Keytruda wins first checkpoint inhibitor lung cancer approval in China; Puma sells rights to Nerlynx in Europe, parts of Africa for $60M upfront

Natalie Grover

Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Mer­ck­'s Keytru­da wins first check­point in­hibitor lung can­cer ap­proval in Chi­na; Puma sells rights to Ner­l­ynx in Eu­rope, parts of Africa for $60M up­front

Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Merck's Keytruda wins first checkpoint inhibitor lung cancer approval in China; Puma sells rights to Nerlynx in Europe, parts of Africa for $60M upfront